Home > Boards > Free Zone > Industry Specific > Israel Stock Ideas

>>> Protalix BioTherapeutics Announces Positive Interim Results from

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gfp927z Member Profile
 
Followed By 61
Posts 23,924
Boards Moderated 74
Alias Born 03/22/05
160x600 placeholder
Google to Stop Selling Ads Based on Your Specific Web Browsing
Google plans to stop selling ads based on individuals' browsing across multiple websites, a change that could hasten upheaval in the digital advertising industry.
Form 8.3 - Willis Towers Watson Plc
U.S. Private Sector Job Growth Slows in February, Missing Expectations -- ADP
Mastercard Issues 10-Year $600 Million Sustainability Bond
IBM Names Keinan as Group President for Independent Managed Infrastructure Services Business
UK Economy to Grow by 4% in 2021, Treasury Chief Says
mRNA Covid-19 Vaccines Are Fast to Make, but Hard to Scale
Chinese Chip Maker SMIC Orders $1.2 Billion in Equipment From ASML
Emerson Electric Names Mike Train Chief Sustainability Officer
Jeep Maker Stellantis Needs Some Tech Star Dust -- Heard on the Street
Boston Scientific Buys Surgical Business to Expand Kidney Stone Management Portfolio
Biden Expects U.S. to Have Enough Vaccines for All Adults by End of May -- 6th Update
Stock Futures Rise on Vaccine, Stimulus Hopes
Hong Kong Won't Appeal Bribery Case Involving Ex-JPMorgan Banker -- Update
Top Company News of the Day
Incyte, Eli Lilly: Baricitinib Meets Main Endpoint in Alopecia Areata Study
Sands to Sell Las Vegas Properties for $6.25 Billion as Company Looks to Asia
FedEx to Invest $2 Billion in Bid to Be Carbon Neutral by 2040
Rheinmetall, HASCO JV Wins Electromotor-Housings Contract in China
Bank Appetite for Bonds Fueled by Capital Holiday
Off-Price Retail Is Fully Priced -- Heard on the Street
Italy's 4Q GDP Contracted Slightly Less Than Previously Estimated
Hong Kong Won't Appeal Ruling in Bribery Case Involving Ex-JPMorgan Banker
Sampo Oyj Sampo Plc: Managers' Transactions (Tetrao SA)
gfp927z   Friday, 01/27/17 11:18:17 AM
Re: None
Post # of 106 
>>> Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis


CARMIEL, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (PLX), announced today positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis (CF) for the first 13 CF patients enrolled in the study. Fifteen patients have been enrolled in, and are expected to complete, the study. alidornase alfa is a plant cell expressed, chemically modified recombinant DNase enzyme resistant to inhibition by actin, which the Company has specifically designed to enhance the enzyme’s efficacy in CF patients.

The phase II trial is a 28-day switch-over study to evaluate the safety and efficacy of alidornase alfa in CF patients previously treated with Pulmozyme®. Participation in the trial is preceded by a two-week washout period from Pulmozyme® before treatment with alidornase alfa via inhalation.

The initial primary efficacy result shows that alidornase alfa improves lung function as demonstrated by a mean absolute increase in the percent predicted forced expiratory volume in one second (ppFEV1) of 4.1 points from baseline. A commercially available small molecule CFTR modulator for the treatment of CF has reported a mean absolute increase in ppFEV1 of 2.5 from baseline in its registration clinical study. This score was achieved while 74% of the patients participating in the trial of the CFTR modulator were also treated with Pulmozyme® on top of the modulator. While this marketed CFTR addresses a certain mutation applicable to less than 50% of CF patients, alidornase alfa is being developed to treat all CF patients.

Sputa available DNA samples were analyzed for approximately half of the patients. A mean reduction of approximately 60% in DNA content from baseline was observed, and a mean reduction of approximately 90% from baseline was observed for sputa visco-elasticity. This data provides further supportive evidence of improved lung function after treatment with alidornase alfa, as demonstrated by the increase in ppFEV1.

No serious adverse events were reported, and all adverse events that occurred during the study were mild and transient in nature.

“We are enthusiastic about the data generated in this trial as we were able to see meaningful improvements in efficacy in a way that have not been reported for a long time in the challenging CF space,” commented Moshe Manor, Protalix’s President and Chief Executive Officer. “We are looking forward to reporting full results from the study before the end of the first quarter of 2017.”

“The preliminary efficacy results of alidornase alfa are very encouraging, even when compared to past trials of approved drugs for the treatment of CF. Although the study was performed on a small number of patients, the data is very encouraging since it shows clinically meaningful results,” said Professor Eitan Kerem, Chairman of Pediatrics, Head of The Cystic Fibrosis Center, Hadassah University Hospital. “I look forward to following the results of upcoming trials of alidornase alfa. If the data continues to be as positive, clearly alidornase alfa will be a key treatment for all CF patients.” <<<






Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences